Asia Standard Hotel Group Limited (HKG:0292)
Hong Kong · Delayed Price · Currency is HKD 0.0800
+0.0070 (9.59%)
Inactive · Last trade price on Sep 24, 2024
Regulus Therapeutics Income Statement
Financials in millions HKD. Fiscal year is April - March.
Millions HKD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
Operating Revenue | 393.2 | 185.02 | 87.33 | 43.03 | 319.1 | Upgrade |
Other Revenue | 498.05 | 741.64 | 902.42 | 934.38 | 804.32 | Upgrade |
| 891.25 | 926.65 | 989.75 | 977.41 | 1,123 | Upgrade | |
Revenue Growth (YoY) | -3.82% | -6.37% | 1.26% | -13.00% | -6.33% | Upgrade |
Cost of Revenue | 114.8 | 64.08 | 41.21 | 27.78 | 194.44 | Upgrade |
Gross Profit | 776.45 | 862.58 | 948.53 | 949.63 | 928.98 | Upgrade |
Selling, General & Admin | 145.91 | 158.62 | 115.59 | 110.39 | 148.39 | Upgrade |
Operating Expenses | 255.13 | 275.91 | 1,314 | 287.7 | 303.88 | Upgrade |
Operating Income | 521.32 | 586.67 | -365.88 | 661.93 | 625.1 | Upgrade |
Interest Expense | -162 | -136.8 | -129.98 | -128.37 | -211.62 | Upgrade |
Earnings From Equity Investments | -2.22 | 0.77 | 0.22 | 1.68 | 1.92 | Upgrade |
Currency Exchange Gain (Loss) | -0.01 | -0.59 | -0.15 | -0.71 | 3.93 | Upgrade |
Other Non Operating Income (Expenses) | -25.01 | -16.75 | -0.28 | -20.82 | -19.75 | Upgrade |
EBT Excluding Unusual Items | 332.07 | 433.3 | -496.07 | 513.71 | 399.58 | Upgrade |
Gain (Loss) on Sale of Investments | -2,660 | -624.16 | -294.33 | 116.67 | -26.47 | Upgrade |
Pretax Income | -2,328 | -190.86 | -790.4 | 630.38 | 373.11 | Upgrade |
Income Tax Expense | -78.35 | 21.93 | -44.41 | 9.07 | -10.48 | Upgrade |
Earnings From Continuing Operations | -2,250 | -212.79 | -745.99 | 621.31 | 383.59 | Upgrade |
Minority Interest in Earnings | 0.06 | -0.01 | -0.4 | 0.19 | -0.58 | Upgrade |
Net Income | -2,250 | -212.79 | -746.38 | 621.51 | 383.01 | Upgrade |
Net Income to Common | -2,250 | -212.79 | -746.38 | 621.51 | 383.01 | Upgrade |
Net Income Growth | - | - | - | 62.27% | 12.74% | Upgrade |
Shares Outstanding (Basic) | 2,018 | 2,018 | 2,018 | 2,018 | 2,018 | Upgrade |
Shares Outstanding (Diluted) | 2,018 | 2,018 | 2,018 | 4,711 | 4,711 | Upgrade |
Shares Change (YoY) | - | - | -57.16% | - | -0.11% | Upgrade |
EPS (Basic) | -1.11 | -0.11 | -0.37 | 0.31 | 0.19 | Upgrade |
EPS (Diluted) | -1.12 | -0.11 | -0.37 | 0.14 | 0.08 | Upgrade |
EPS Growth | - | - | - | 60.31% | 12.62% | Upgrade |
Free Cash Flow | -166.99 | 820.15 | -1,014 | 1,490 | 381.59 | Upgrade |
Free Cash Flow Per Share | -0.08 | 0.41 | -0.50 | 0.32 | 0.08 | Upgrade |
Dividend Per Share | - | - | - | 0.006 | - | Upgrade |
Gross Margin | 87.12% | 93.08% | 95.84% | 97.16% | 82.69% | Upgrade |
Operating Margin | 58.49% | 63.31% | -36.97% | 67.72% | 55.64% | Upgrade |
Profit Margin | -252.42% | -22.96% | -75.41% | 63.59% | 34.09% | Upgrade |
Free Cash Flow Margin | -18.74% | 88.51% | -102.43% | 152.45% | 33.97% | Upgrade |
EBITDA | 575.01 | 647.17 | -296.84 | 731.93 | 703.12 | Upgrade |
EBITDA Margin | 64.52% | 69.84% | -29.99% | 74.88% | 62.59% | Upgrade |
D&A For EBITDA | 53.69 | 60.5 | 69.04 | 70 | 78.02 | Upgrade |
EBIT | 521.32 | 586.67 | -365.88 | 661.93 | 625.1 | Upgrade |
EBIT Margin | 58.49% | 63.31% | -36.97% | 67.72% | 55.64% | Upgrade |
Effective Tax Rate | - | - | - | 1.44% | - | Upgrade |
Revenue as Reported | 891.25 | 926.65 | 989.75 | 977.41 | 1,123 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.